FDA Grants Fast Track Designation to MVR-T3011 for Pretreated HNSCC
The oncolytic virus product MVR-T3011 has received FDA fast track designation for recurrent or metastatic head and neck squamous cell cancer.
The oncolytic virus product MVR-T3011 has received FDA fast track designation for recurrent or metastatic head and neck squamous cell cancer.
Dr. Meagan Krupa came to MD Anderson from Alaska after watching its specialists expertly guide a relative’s local cancer care. Here, she received a corrected…
Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.
In February 2022, the U.S. Food and Drug Administration approved ciltacabtagene autoleucel, a chimeric antigen receptor (CAR) T cell therapy targeting the B-cell maturation antigen…
Anupama Rao, MD, Great Ormond Street Hospital, London, UK, highlights the necessity for increasing clinician awareness in regard to the presence of germline predispositions to…
In the first clinical trial of dose-adjusted EPOCH along with inotuzumab ozogamicin (InO) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), Fred…
AbstractBackground. The impact of ongoing efforts to decrease opioid use on patients with cancer remains undefined. Our objective was to determine trends in new
An @OSUCCC_James pulmonologist describes the new mobile lung cancer screening unit that will be traveling throughout Buckeye state to offer screenings to underserved areas.
If the FDA Oncology Center of Excellence (OCE) began an “innovation challenge” in oncology drug development, what would that look like? To access this subscriber-only…
This cohort study examines the role of comprehensive bridging radiotherapy in the setting of chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
Knowing about the most common cancers that affect women and how to lower your risk or find them early may help save your life or…